Retrospective Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 26, 2019; 7(12): 1403-1409
Published online Jun 26, 2019. doi: 10.12998/wjcc.v7.i12.1403
Feasibility of prostatectomy without prostate biopsy in the era of new imaging technology and minimally invasive techniques
Nian-Zeng Xing, Ming-Shuai Wang, Qiang Fu, Fei-Ya Yang, Chang-Ling Li, Ya-Jian Li, Su-Jun Han, Ze-Jun Xiao, Hao Ping
Nian-Zeng Xing, Fei-Ya Yang, Chang-Ling Li, Ya-Jian Li, Su-Jun Han, Ze-Jun Xiao, Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Ming-Shuai Wang, Institute of Urology, Capital Medical University, Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China
Qiang Fu, Department of Urology, Shandong Provincial Hospital, Jinan 250021, Shandong Province, China
Hao Ping, Department of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China
Author contributions: All authors helped to perform the study; Xing NZ and Wang MS are co-first authors; Xing NZ contributed to study conception and design and manuscript writing; Wang MS contributed to study design, manuscript writing, and data analysis; Yang FY, Li YJ, Han SJ, Xiao ZJ, and Li CL contributed to data collection and manuscript writing; Ping H and Fu Q contributed to manuscript writing and data analysis.
Institutional review board statement: As the retrospective study and data analysis were performed anonymously, this study was exempt from the ethical approval.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All authors declare no conflicts of interest related to this article.
Data sharing statement: No additional data are available.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Nian-Zeng Xing, MD, PhD, Chairman, Professor, Surgeon, Director, Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Pan Jia Yuan Nan Li, Chaoyang District, Beijing 100021, China. xingnianzeng@hotmail.com
Telephone: +86-18612023952
Received: February 17, 2019
Peer-review started: February 18, 2019
First decision: April 18, 2019
Revised: April 25, 2019
Accepted: May 10, 2019
Article in press: May 11, 2019
Published online: June 26, 2019
Processing time: 128 Days and 21 Hours
Core Tip

Core tip: The ability of ultrasound-guided prostate biopsy to detect prostate cancer is limited. Maybe prostate biopsy can be exempt before surgery when multi-parameter prostate magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography/computed tomography are both positive. The current practice of mandating a prostatic biopsy before prostatectomy should be reconsidered in the era of new imaging technology and minimally invasive techniques.